Earnings Results
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is scheduled to report its Q2 earnings results on July 28, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-0.22, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at , down from a year ago.
Company Overview
The stock currently trades at $3.73 with a market capitalization of $692.6M.
Ahead of Fulcrum Therapeutics, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Fulcrum Therapeutics, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Fulcrum Therapeutics, Inc. Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q1 (Apr 2026) | $-0.25 | $-0.30 | +16.7% |
| Q4 (Feb 2026) | $-0.31 | $-0.31 | +0.0% |
| Q3 (Sep 2025) | $-0.31 | $-0.30 | -3.5% |
| Q2 (Jun 2025) | $-0.28 | $-0.30 | +5.3% |
Related Tools: Earnings Calendar | View FULC Stock Page
Frequently Asked Questions
When does Fulcrum Therapeutics, Inc. report earnings?
Check the latest earnings dates on our FULC earnings page or the Earnings Calendar.
Did FULC beat earnings estimates?
See the full Q2 results including EPS actual vs estimate on our FULC earnings page.